Q-omics provides the consensus-scored PABPC1L2A profile across patient tissues and cancer cell-line models. PABPC1L2A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PABPC1L2A is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, PABPC1L2A RNA expression shows 10,062 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, COAD, and GBM as cancer lineages where PABPC1L2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PABPC1L2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PABPC1L2A survival associations across molecular data types. PABPC1L2A RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PABPC1L2A RNA expression–survival associations across cancer types. High PABPC1L2A expression shows unfavorable associations in KIRP, COAD and LIHC, but favorable associations in UCS, LUAD and CHOL. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PABPC1L2A RNA expression.
This table summarizes PABPC1L2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PABPC1L2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PABPC1L2A shows lower tumor expression in COAD, THCA and HNSC and higher tumor expression in PRAD, LUAD and LUSC. The COAD box plot shows higher PABPC1L2A RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p < 0.001).
This table shows molecular features associated with PABPC1L2A in patient tissues and cancer cell lines. In patient samples, PABPC1L2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PABPC1L2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
